003850.KS
Boryung Pharmaceutical Co., Ltd. [003850.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
003850.KS Stock Summary
Top 10 Correlated ETFs
003850.KS
Top 10 Correlated Stocks
003850.KS
In the News
003850.KS Financial details
Company Rating
Buy
Market Cap
756.8B
Income
40.2B
Revenue
859.63B
Book val./share
8331.34
Cash/share
304.48
Dividend
-
Dividend %
-
Employees
1.4K
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
22.22
Forward P/E
-
PEG
-55.32
P/S
0.92
P/B
1.15
P/C
36.29
P/FCF
-10.07
Quick Ratio
-
Current Ratio
1.73
Debt / Equity
0.37
LT Debt / Equity
0.28
-
-
EPS (TTM)
610.37
EPS next Y
-
EPS next Q
-
EPS this Y
-4.01%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.4%
Revenue last 5Y
10.4%
Revenue Q/Q
11%
EPS Q/Q
-53.12%
-
-
-
-
SMA20
-14.48%
SMA50
-8.55%
SMA100
14.56%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
5%
ROC
0.06%
Gross Margin
40%
Oper. Margin
6%
Profit Margin
3%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7440.0-13750.0
52W High
-19.64%
52W Low
+48.52%
RSI
36
Rel Volume
0.39
Avg Volume
437.66K
Volume
168.57K
Perf Week
-2.21%
Perf Month
-9.8%
Perf Quarter
16.07%
Perf Half Y
6.05%
-
-
-
-
Beta
0.684
-
-
Volatility
207.34%, 873.89%
Prev Close
-1.43%
Price
11050
Change
2.31%
003850.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 9.27K | 9.47K | 10.04K | 11.54K | 13.05K | |
| Net income per share | 569.48 | 452.86 | 688.72 | 635.91 | 610.38 | |
| Operating cash flow per share | 830.64 | 754.45 | 962.7 | 422.18 | 641.06 | |
| Free cash flow per share | -384.51 | -199.9 | 13.6 | -1.44K | 286.58 | |
| Cash per share | 83.71 | 1.53K | 3.22K | 271.96 | 304.48 | |
| Book value per share | 5K | 5.73K | 7.58K | 7.83K | 8.33K | |
| Tangible book value per share | 4.72K | 4.8K | 6.1K | 5.05K | 5.71K | |
| Share holders equity per share | 5K | 5.73K | 7.58K | 7.83K | 8.33K | |
| Interest debt per share | 1.75K | 3.29K | 3.52K | 3.25K | 3.23K | |
| Market cap | 697.86B | 923.12B | 912.48B | 590.3B | 775.9B | |
| Enterprise value | 792.11B | 1089.09B | 977.28B | 782.47B | 963.63B | |
| P/E ratio | 21.66 | 34.37 | 21.2 | 14.09 | 19.3 | |
| Price to sales ratio | 1.33 | 1.64 | 1.45 | 0.78 | 0.9 | |
| POCF ratio | 14.85 | 20.63 | 15.17 | 21.22 | 18.38 | |
| PFCF ratio | -32.08 | -77.87 | 1.07K | -6.2 | 41.11 | |
| P/B Ratio | 2.47 | 2.72 | 1.93 | 1.14 | 1.41 | |
| PTB ratio | 2.47 | 2.72 | 1.93 | 1.14 | 1.41 | |
| EV to sales | 1.51 | 1.94 | 1.56 | 1.03 | 1.12 | |
| Enterprise value over EBITDA | 12.91 | 16.22 | 9.63 | 7.29 | 8.6 | |
| EV to operating cash flow | 16.85 | 24.34 | 16.24 | 28.13 | 22.82 | |
| EV to free cash flow | -36.41 | -91.87 | 1.15K | -8.22 | 51.05 | |
| Earnings yield | 0.05 | 0.03 | 0.05 | 0.07 | 0.05 | |
| Free cash flow yield | -0.03 | -0.01 | 0 | -0.16 | 0.02 | |
| Debt to equity | 0.35 | 0.56 | 0.45 | 0.4 | 0.37 | |
| Debt to assets | 0.19 | 0.3 | 0.26 | 0.23 | 0.22 | |
| Net debt to EBITDA | 1.54 | 2.47 | 0.64 | 1.79 | 1.67 | |
| Current ratio | 1.67 | 2.57 | 2.8 | 1.22 | 1.93 | |
| Interest coverage | 628.75 | 11.96 | 15.51 | 9.24 | 7.09 | |
| Income quality | 1.46 | 1.67 | 1.4 | 0.66 | 1.05 | |
| Dividend Yield | 0 | 0 | 0 | 0.01 | 0.01 | |
| Payout ratio | 0.08 | 0.16 | 0.1 | 0.16 | 0.16 | |
| Sales general and administrative to revenue | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.07 | 0.06 | 0.06 | 0.05 | 0.06 | |
| Intangibles to total assets | 0.03 | 0.09 | 0.11 | 0.21 | 0.19 | |
| Capex to operating cash flow | -1.46 | -1.26 | -0.99 | -4.42 | -0.55 | |
| Capex to revenue | -0.13 | -0.1 | -0.09 | -0.16 | -0.03 | |
| Capex to depreciation | -3.95 | -2.05 | -1.85 | -3.27 | -0.53 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8K | 7.64K | 10.84K | 10.59K | 10.7K | |
| ROIC | 0.08 | 0.06 | 0.06 | 0.06 | 0.07 | |
| Return on tangible assets | 0.07 | 0.05 | 0.06 | 0.06 | 0.05 | |
| Graham Net | -1.38K | -1.39K | -149.55 | -2.53K | -2.05K | |
| Working capital | 92.64B | 192.79B | 281.36B | 60.9B | 186.41B | |
| Tangible asset value | 267.28B | 284.59B | 381.49B | 332.77B | 376.38B | |
| Net current asset value | 7.18B | 7.95B | 82.99B | -37.59B | 14.39B | |
| Invested capital | 0.35 | 0.56 | 0.45 | 0.4 | 0.37 | |
| Average receivables | 131.66B | 124.03B | 116.54B | 131.43B | 155B | |
| Average payables | 54B | 52.86B | 55.02B | 75.92B | 79.87B | |
| Average inventory | 80.44B | 90.27B | 103.24B | 137.81B | 177.21B | |
| Days sales outstanding | 92.17 | 75.15 | 68.31 | 69.82 | 69.86 | |
| Days payables outstanding | 69.3 | 53.6 | 61.97 | 72.73 | 48.14 | |
| Days of inventory on hand | 103.05 | 105.48 | 111.81 | 132.56 | 131.62 | |
| Receivables turnover | 3.96 | 4.86 | 5.34 | 5.23 | 5.22 | |
| Payables turnover | 5.27 | 6.81 | 5.89 | 5.02 | 7.58 | |
| Inventory turnover | 3.54 | 3.46 | 3.26 | 2.75 | 2.77 | |
| ROE | 0.11 | 0.08 | 0.09 | 0.08 | 0.07 | |
| Capex per share | -1.22K | -954.35 | -949.1 | -1.87K | -354.48 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.06K | 3.09K | 3.28K | 3.16K | 3.51K | |
| Net income per share | -96.46 | 172.35 | 171.84 | 181.22 | 84.96 | |
| Operating cash flow per share | -509.5 | -18.84 | 348.9 | 128.48 | 182.52 | |
| Free cash flow per share | -2.05K | -74.72 | 235.86 | 69.8 | 55.63 | |
| Cash per share | 272.02 | 1.23K | 277.84 | 261.56 | 304.48 | |
| Book value per share | 7.83K | 7.91K | 8.09K | 8.29K | 8.33K | |
| Tangible book value per share | 5.05K | 5.19K | 5.4K | 5.59K | 5.71K | |
| Share holders equity per share | 7.83K | 7.91K | 8.09K | 8.29K | 8.33K | |
| Interest debt per share | 3.19K | 4.21K | 3.18K | 3.1K | 3.12K | |
| Market cap | 590.16B | 573.69B | 540.76B | 665.24B | 775.9B | |
| Enterprise value | 782.33B | 832.79B | 732.61B | 855.25B | 963.63B | |
| P/E ratio | -23.22 | 12.63 | 11.94 | 13.93 | 34.66 | |
| Price to sales ratio | 2.93 | 2.81 | 2.5 | 3.19 | 3.36 | |
| POCF ratio | -17.59 | -462.37 | 23.53 | 78.61 | 64.54 | |
| PFCF ratio | -4.36 | -116.56 | 34.81 | 144.7 | 211.74 | |
| P/B Ratio | 1.14 | 1.1 | 1.01 | 1.22 | 1.41 | |
| PTB ratio | 1.14 | 1.1 | 1.01 | 1.22 | 1.41 | |
| EV to sales | 3.88 | 4.09 | 3.39 | 4.11 | 4.17 | |
| Enterprise value over EBITDA | 302.86 | 10.5 | 8.22 | 10.41 | 38.3 | |
| EV to operating cash flow | -23.31 | -671.19 | 31.88 | 101.07 | 80.15 | |
| EV to free cash flow | -5.79 | -169.21 | 47.16 | 186.02 | 262.97 | |
| Earnings yield | -0.01 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Free cash flow yield | -0.23 | -0.01 | 0.03 | 0.01 | 0 | |
| Debt to equity | 0.4 | 0.53 | 0.39 | 0.37 | 0.37 | |
| Debt to assets | 0.23 | 0.29 | 0.23 | 0.22 | 0.22 | |
| Net debt to EBITDA | 74.4 | 3.27 | 2.15 | 2.31 | 7.46 | |
| Current ratio | 1.22 | 1.57 | 1.78 | 1.73 | 1.93 | |
| Interest coverage | -4.39 | 91.56 | 7.37 | 8.18 | 5.84 | |
| Income quality | 5.28 | -0.11 | 2.03 | 0.71 | 2.15 | |
| Dividend Yield | 0 | 0 | 0.01 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0.58 | 0 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.31 | 0.32 | 0.31 | 0.02 | |
| Research and developement to revenue | 0.05 | 0.05 | 0.05 | 0.05 | 0.07 | |
| Intangibles to total assets | 0.21 | 0.19 | 0.2 | 0.19 | 0.19 | |
| Capex to operating cash flow | 3.03 | 2.97 | -0.32 | -0.46 | -0.7 | |
| Capex to revenue | -0.5 | -0.02 | -0.03 | -0.02 | -0.04 | |
| Capex to depreciation | -10.12 | -0.34 | -0.67 | -0.34 | -0.76 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.12K | 5.54K | 5.59K | 5.81K | 3.99K | |
| ROIC | -0.01 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Return on tangible assets | -0.01 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Graham Net | -2.53K | -2.39K | -2.26K | -2.3K | -2.05K | |
| Working capital | 60.9B | 146.33B | 156.27B | 165.6B | 186.41B | |
| Tangible asset value | 332.77B | 341.88B | 355.36B | 368.12B | 376.38B | |
| Net current asset value | -37.59B | -29.11B | -14.65B | 109.87M | 14.39B | |
| Invested capital | 0.4 | 0.53 | 0.39 | 0.37 | 0.37 | |
| Average receivables | 142.27B | 145.33B | 150.3B | 159.39B | 163.94B | |
| Average payables | 96.39B | 81.95B | 83.64B | 102.55B | 90.41B | |
| Average inventory | 156.38B | 165.68B | 169.73B | 185.96B | 194.5B | |
| Days sales outstanding | 64.98 | 64.11 | 64.68 | 70.58 | 64.04 | |
| Days payables outstanding | 65.75 | 53.2 | 66.34 | 79.47 | 46.79 | |
| Days of inventory on hand | 119.84 | 120.56 | 122.28 | 142.11 | 127.94 | |
| Receivables turnover | 1.39 | 1.4 | 1.39 | 1.28 | 1.41 | |
| Payables turnover | 1.37 | 1.69 | 1.36 | 1.13 | 1.92 | |
| Inventory turnover | 0.75 | 0.75 | 0.74 | 0.63 | 0.7 | |
| ROE | -0.01 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Capex per share | -1.54K | -55.88 | -113.03 | -58.67 | -126.89 |
003850.KS Frequently Asked Questions
What is Boryung Pharmaceutical Co., Ltd. stock symbol ?
Boryung Pharmaceutical Co., Ltd. is a KR stock and trading under the symbol 003850.KS
What is Boryung Pharmaceutical Co., Ltd. stock quote today ?
Boryung Pharmaceutical Co., Ltd. stock price is $11050 today.
Is Boryung Pharmaceutical Co., Ltd. stock public?
Yes, Boryung Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 437.66K
- Market Capitalization 756.8B
- Employee 1.4K
- CEO Mr. Jay Kim
- Headquarters Seoul,KR
- IPO Date 2000-01-04
-
Website
https://www.boryung.co.kr 
Boryung Corporation produces and sells pharmaceutical products in South Korea. The company offers cardiovascular products, anticancer products, gastrointestinal products, and API's. It also exports its products to approximately 50 countries on 6 continents, including Japan, China, the Southeast Asia, the Middle East, Europe, South America, and Africa. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is based in Seoul, South Korea.
